Skip to main content

Attovia Therapeutics, Inc.

corporate_fare Company Profile

Attovia Therapeutics, Inc.

ATTO·NASDAQ·Life Sciences·CIK 0002058707

Attovia reported a $22.3M Q3 net loss with $395.9M in cash, enough to fund operations into 2030, and confirmed two Phase 2 ATTO-1310 trials plus two Phase 1 starts are on track for the first half of 2027.

Attovia Therapeutics, Inc. (NASDAQ:ATTO) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 8 items for ATTO at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-09, rated 7/10. Across its 8 most recent items scored 7 or higher, the top rating is 8/10, with 5 rated 8 or above. Recent SEC coverage for ATTO spans 8-K, 10-Q, 4/A, 4.

Recent high-impact activity:

  • Attovia Posts Q3 Loss of $22.3M With $395.9M Cash and Phase 2 Starts Set for 1H 2027
  • Attovia's ATTO-1310 Holds 82% Itch Response at Week 12 After Single Dose
  • Attovia Reports Q2 2026 Loss of $20.7M; IPO Proceeds Extend Runway into 2030
  • Attovia's ATTO-1310 Shows Clinical Proof of Concept; Cash Runway Extended to 2030
  • Director Colin Walsh's Amended Form 4 Reveals $12.5M Purchase and Previously Undisclosed Equity Swaps

Short Interest & Short Volume

4.50 days to cover

FINRA reported short interest of 1,587,537 shares in ATTO as of the October 30, 2026 settlement, a 9.3% increase from the prior period — about 4.5 days to cover at its recent average daily volume. On November 20, 2026, 63.0% of ATTO volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)1,587,537 shares as of October 30, 2026
Change vs prior period▲ 9.3%
Days to cover4.50 at avg daily volume of 352,555
Daily short volume (FINRA facilities)63.0% of 124,282 shares on November 20, 2026
5-day average short volume73.8%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

$15.1
52-week range · as of 2026-11-09 $12.94 – $28
Market cap
$690.26M
Volume
372.2K (1.2× avg)
3-mo avg 312.4K
Live data · 2026-11-21 14:19 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed ATTO - Latest Insights

ATTO
Nov 09, 2026, 4:10 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $15.96
Real-time Price: $15.10 info
Change: -$0.860 (-5%) info
Market Cap: $690.259M info
ATTO
Nov 05, 2026, 4:05 PM EST
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $14.95
Real-time Price: $15.10 info
Change: +$0.150 (+1%) info
Market Cap: $690.259M info
ATTO
Sep 02, 2026, 4:21 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $23.13
Real-time Price: $15.10 info
Change: -$8.03 (-35%) info
Market Cap: $690.259M info
ATTO
Sep 02, 2026, 4:05 PM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $23.13
Real-time Price: $15.10 info
Change: -$8.03 (-35%) info
Market Cap: $690.259M info
ATTO
Aug 28, 2026, 5:38 PM EDT
Filing Type: 4/A
Importance Score:
7
Price at Filing: $20.70
Real-time Price: $15.10 info
Change: -$5.60 (-27%) info
Market Cap: $690.259M info
ATTO
Aug 13, 2026, 9:52 PM EDT
Filing Type: 4
Importance Score:
8
Price at Filing: $19.18
Real-time Price: $15.10 info
Change: -$4.08 (-21%) info
Market Cap: $690.259M info
ATTO
Aug 11, 2026, 5:08 PM EDT
Filing Type: SCHEDULE 13D
Importance Score:
8
Price at Filing: $18.65
Real-time Price: $15.10 info
Change: -$3.55 (-19%) info
Market Cap: $690.259M info
ATTO
Aug 06, 2026, 5:35 PM EDT
Filing Type: 4
Importance Score:
8
Price at Filing: $20.56
Real-time Price: $15.10 info
Change: -$5.46 (-27%) info
Market Cap: $690.259M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets